Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124116 | 0.89 | GRM5 (0.46) | GRM5ADRB1KMT2A | |
| SCHEMBL5128492 | 0.84 | GRM5 (0.43) | GRM5 | |
| SCHEMBL5129681 | 0.81 | GRM5 (0.46) | GRM5AVPR1ANPSR1 | |
| SCHEMBL5122918 | 0.81 | GRM5 (0.54) | GRM5ADRB1ALDH1A1 | |
| SCHEMBL5124137 | 0.80 | GRM5 (0.50) | GRM5ADRB1ALDH1A1 | |
| SCHEMBL5125859 | 0.80 | GRM5 (0.47) | GRM5ADRB1ALDH1A1 | |
| SCHEMBL5122183 | 0.79 | GRM5 (0.43) | GRM5 | |
| SCHEMBL5128572 | 0.79 | GRM5 (0.49) | GRM5 | |
| SCHEMBL5120508 | 0.78 | GRM5 (0.41) | GRM5 | |
| SCHEMBL5129376 | 0.78 | GRM5 (0.46) | GRM5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1856107-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | Novartis AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089700-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | NOVARTIS AG (CH) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885AR 2249/4885AVPR1A 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.